DaVita (DVA)
(Delayed Data from NYSE)
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Is Most-Watched Stock DaVita Inc. (DVA) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching DaVita HealthCare (DVA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Elevance Health (ELV) Brand Inks Deal to Better Serve Georgia
by Zacks Equity Research
Elevance Health's (ELV) brand, Anthem Blue Cross and Blue Shield, collaborates to make the benefits of Piedmont's healthcare network available to its members across specific Georgia regions.
Why You Should Retain Integer Holdings (ITGR) Stock for Now
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.
Why You Should Retain Inari Medical (NARI) Stock for Now
by Zacks Equity Research
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Shockwave Medical's (SWAV) Reducer Receives Positive Results
by Zacks Equity Research
Shockwave Medical (SWAV) announces the 'real-world' results of the REDUCER-I study, which is intended to collect long-term outcomes on Shockwave Reducer, a novel treatment for refractory angina.
Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes
by Zacks Equity Research
Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.
Here's Why Investors Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.
Thermo Fisher (TMO) Launches TSX Universal Series ULT Freezers
by Zacks Equity Research
Thermo Fisher's (TMO) new ENERGY STAR-certified TSX Universal Series ULT Freezers deliver tighter temperature control and faster recovery times.
Why the Market Dipped But DaVita HealthCare (DVA) Gained Today
by Zacks Equity Research
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $133.73, denoting a +0.09% change from the preceding trading day.
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Philips (PHG) Boosts Patient Monitoring With smartQare Deal
by Zacks Equity Research
Philips (PHG) partners with smartQare to integrate the latter's viQtor solution, boosting its patient monitoring solutions portfolio.
BD's (BDX) Latest Product to Offer Wider Access to Researchers
by Zacks Equity Research
The latest worldwide commercial availability of BD's (BDX) cell sorters is set to expand researchers' capabilities to transform research and cell-based therapeutic development across numerous fields.
Silk Road Medical's (SILK) New Launch to Aid Its TCAR Portfolio
by Zacks Equity Research
Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.
Abbott (ABT) Faces Low Testing Demand, Currency Headwinds
by Zacks Equity Research
Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.
IM Cannabis (IMCC) Expands Business in Germany With New Alliance
by Zacks Equity Research
The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.
Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATC
by Zacks Equity Research
Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
by Zacks Equity Research
AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
Abbott (ABT) Receives FDA's Approval for the TriClip TEER System
by Zacks Equity Research
Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.
Diagnosing the Economy Ahead of World Health Day: 6 Picks
by Sweta Killa
Similar to the six vital nutrients required for good health, we have examined the six pillars that support the economy and zeroed in on stocks that have a Zacks Rank #1 (Strong Buy) or 2 (Buy) and a higher market cap in their respective sectors.
Henry Schein (HSIC) Buys TriMed to Expand in Orthopedic Space
by Zacks Equity Research
According to Henry Schein (HSIC), the upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion.
3 Soaring, Highly-Ranked Value Stocks to Buy in April
by Benjamin Rains
3 highly-ranked Zacks stocks that offer an attractive combination of impressive valuations, soaring stock prices, and long-term upside in crucial, non-flashy industries.
GE HealthCare's (GEHC) New Launch to Enhance Cardiac Care
by Zacks Equity Research
GE HealthCare's (GEHC) latest offering is likely to expand access to cardiac care by enabling more medical professionals to be able to capture cardiac images.
Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS
by Zacks Equity Research
Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process.